Grade 3/4 AEs were observed in 10 (45%) patients, including neutropenia (32%, n = 7), hypofibrinogenemia (18%, n = 4), leukopenia (9%, n = 2), anemia (5%, n = 1), thrombocytopenia (5%, n = 1), hypoalbuminemia (5%, n = 1), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation (5%, n = 1), and heart failure (5%, n = 1), which were manageable and led to no discontinuation of treatment. This evidence concerns the gene GPT and Hypofibrinogenemia.